Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...

Should We Rethink Nuclear Power?

While it seems to fly in the face of everything we believe and have been taught about nuclear power, it may actually be the safest form of power production that we have. Ironically, the immense potency of the power of splitting an atom is simultaneously what makes nuclear weap...

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results

The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. In a press release issued September 24, PhaseBio Pharmaceuticals Inc. (PHAS...

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...

One of the Best Valued Companies in the Digital Assets Space

(Click image to play video) The booming financial technology, or fintech, sector is currently one of the hottest and most risk-adverse in capital markets today. And one Canada-based company is gaining significant traction and investor interest in this cutting-ed...

Buzz on the Bullboards: The Top Last-Minute Movers of 2021

Expecting the markets to be relaxed heading into the holidays? Hardly. Many investors and brokers know that this is the time to shine. With every twist and turn the global economy has been throwing our way, the right move is staying active. This past week, it seems ma...

Biopharma's Early Data Show Immunotherapy's Efficacy in Ovarian Cancer

The "encouraging" data for this drug candidate as a monotherapy is the focus of an H.C. Wainwright & Co. report. In a March 26 research note, analyst Joseph Pantginis reported that IMV Inc.'s (IMV:TSX; IMMVD:OTCQX) preliminary monotherapy data confirmed the efficacy o...

San Diego Biopharma Features 'Strong and Balanced Pipeline'

An H.C. Wainwright & Co. report discussed what sets this company's asset apart from similar products. In a March 21 research note, H.C. Wainwright & Co. analyst Andrew Fein wrote that MEI Pharma Inc.'s (MEIP:NASDAQ) oral PK3K delta inhibitor, ME-401, differentiates it...

'Pivotal Topline Up Next' for Biotech's Phase 3 Cardiac Clinical Trial

A study update and the next steps to advance the therapeutic were covered in a ROTH Capital Partners report. In an April 25 research note, ROTH Capital Partners analyst Jotin Marango reported that the last required major adverse cardiac event, the 250th, occ...

Trial Milestone Reached; U.K.-Based Biopharma Gets $15 Million

The first patient has been treated in the second cohort of a Phase 2 study of a gene therapy targeting Parkinson's disease, explained an H.C. Wainwright & Co. report. In an April 30 research note, analyst Joseph Pantginis reported that Oxford Biomedica Plc ...
1 2 3 4 5 6